Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
VistaGen Therapeutics, Inc. (VTGN) had Return on Tangible Equity of -29.27% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$0.26M |
|
$-19.42M |
|
-- |
|
$0.26M |
|
$20.31M |
|
$-20.05M |
|
$0.64M |
|
$-19.42M |
|
$-19.42M |
|
$-19.42M |
|
$-19.42M |
|
$-19.42M |
|
$-19.42M |
|
$-20.05M |
|
$-20.14M |
|
35.75M |
|
35.75M |
|
$-0.54 |
|
$-0.54 |
|
| Balance Sheet Financials | |
$78.93M |
|
$0.52M |
|
$2.00M |
|
$80.93M |
|
$13.64M |
|
-- |
|
$0.95M |
|
$14.59M |
|
$66.34M |
|
$66.34M |
|
$66.34M |
|
38.89M |
|
| Cash Flow Statement Financials | |
$-32.60M |
|
$-0.88M |
|
$29.14M |
|
$67.13M |
|
$62.79M |
|
$-4.34M |
|
$2.01M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.79 |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
100.00% |
|
-7772.48% |
|
-7772.48% |
|
-- |
|
-7525.97% |
|
-7525.97% |
|
$-32.73M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-29.27% |
|
|
Return on Tangible Equity |
-29.27% |
-23.99% |
|
-29.27% |
|
$1.71 |
|
$-0.92 |
|
$-0.91 |
|